Aisla Bosworth

Learn More
British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (the first two years) R. Luqmani, S. Hennell, C. Estrach, F. Birrell, A. Bosworth, G. Davenport, C. Fokke, N. Goodson, P. Jeffreson, E. Lamb, R. Mohammed, S. Oliver, Z. Stableford, D. Walsh, C. Washbrook and F. Webb on(More)
Inflammatory arthritis, and especially rheumatoid arthritis (RA), is common and affects over 1% of the population. Even in the 21st century, the prognosis of RA remains uncertain. It runs a variable and unpredictable course. Several longitudinal studies have demonstrated the progressive course of the disease, leading to joint destruction and deformity and,(More)
OBJECTIVES The Government Department of Health (England) has set a target that by 2008 patients on pathways that do or may involve medical or surgical consultant-led care should wait no longer than 18 weeks from referral to start of definitive treatment. Department of Health guidance must be interpreted and applied to patients with rheumatological problems.(More)
RA is a chronic multisystem inflammatory disorder with a prevalence of 0.5 1% in the general population. The management of RA has evolved considerably in the last few decades and newer therapies continue to be developed. Tocilizumab (TCZ) [1] is a humanized anti-IL-6 receptor (anti-IL-6R) antibody licensed for use in combination with MTX for the treatment(More)
  • 1